Skip to main content
Premium Trial:

Request an Annual Quote

As Third Wave Stock Continues Sliding, Director Buys 3,500 Shares

NEW YORK, March 3 (GenomeWeb News) - Third Wave Technologies Director Brunner Gordon yesterday bought 3,500 shares in his company, as the stock continued to slide for the seventh consecutive day since Third Wave reported  lackluster fourth-quarter earnings on Feb. 23.


Third Wave's stock was down 7.35 percent, or $.44, at $5.55 in mid-afternoon trading today. The stock has shed 27 percent of its value since the fourth-quarter earnings were reported on Feb. 23. The shares last traded at this level in early September.


Investors continued dumping the stock after two investment banks -- one on  Feb. 23 and another on  March 1 -- downgraded their ratings of Third Wave.


Gordon bought the stock as the share price reached $6.22, and he now owns a total of 39,500 shares in the company, according to, a web site that follows insider transactions.


As GenomeWeb News  reported on Feb. 23, Third Wave said total revenues for the three-month period ended Dec. 31, 2004, fell 16.5 percent, while net losses tripled.


Total receipts for the three-month period ended Dec. 31, 2004, fell to $8.1 million from $9.7 million during the same quarter in 2003. Third Wave said that more than half, or $4.7 million, of total revenues were derived from clinical molecular diagnostics, meaning that this business segment grew almost 90 percent compared to the fourth quarter of 2003.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.